7 Drug Stocks To Consider As Biosimilars Pick Up Pace

Interest in biosimilars has picked up considerably with Pfizer, Inc.’s announcement this week regarding its plans to launch a biosimilar version of Johnson & Johnson’s blockbuster drug, Remicade, in late November.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.